Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer.
|
29969677 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
|
29247488 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present results indicated that ABCG2 may relieve oxidative stress and inflammatory response by inhibiting the NF-κB signaling pathway in cell models, and may thus play a potential protective role in CRC.
|
30066914 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
|
29436100 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
With a goal to evaluate the clinical significance of ABCG2 measurements, we here review the current literature on ABCG2 in relation to irinotecan treatment in CRC patients.
|
28880238 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The underlying mechanism(s) for ABCG2 under-expression in CRC is currently not known.
|
27253631 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Together, these data show that ABCG2 expression correlates with the presence of CD133-positive cancer cells, and thus is a possible therapeutic target for colorectal cancer.
|
27449042 |
2016 |
Colorectal Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In order to examine the ABCG2 expression level and identify the methylation status, RT-PCR, qRT-PCR analysis, MS-PCR and bisulfite sequencing were conducted on 32 CRC cell lines.
|
26497773 |
2016 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, here, we provide validated results to guide future studies on the associations between ABCG2 immunoreactivity in tumor cells and the benefits of chemotherapeutic treatment in patients with CRC.
|
27257141 |
2016 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ABCC2 and ABCG2 mRNA levels were assessed in intestinal tissue from 122 CRC cases, 106 adenoma cases (12 with severe dysplasia, 94 with mild-moderate dysplasia) and from 18 controls with normal endoscopy.
|
25793771 |
2015 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a three-way analysis, both ABCB1/rs1045642 and ABCG2/rs2231137 in combination with IL10/rs3024505 interacted with fiber intake in relation to risk of CRC (P(int) = 0.0007 and 0.009).
|
26109419 |
2015 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the effect of ABCG2 dysregulation on cancer cell sensitivity to chemotherapy using pairs of snap-frozen paraffin-embedded archival blocks of human colorectal cancer tissues and their matched non-cancerous colon tissues from CRC patients.
|
26386386 |
2015 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.
|
26176272 |
2015 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ABCG2 expression is associated with the tumor response to FOLFOX in patients with metastatic CRC.
|
23558935 |
2013 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
|
23960095 |
2013 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, miR-222 targeting ADAM-17, a disintegrin and metalloproteinase, and miR-328 interacting with ABCG2, an ABC transporter, may overcome drug resistance of cancer cells. microRNAs may be considered in wide-range application to facilitate CRC metastasis diagnosis, prognosis, prediction and therapy, however, further clinical, epidemiological and in vitro studies should be conducted to verify their utility.
|
23173124 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The role of ABC transporters in progression and clinical outcome of colorectal cancer.
|
22294766 |
2012 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate the effect of coffee on intestinal transporters, we investigated its effect on expression of the breast cancer resistance protein (BCRP/ABCG2) in a human colorectal cancer cell line, Caco-2.
|
21963506 |
2011 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Downregulation of breast cancer resistance protein in colon adenomas reduces cellular xenobiotic resistance and leads to accumulation of a food-derived carcinogen.
|
21544799 |
2011 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
From the present results expression of ABCG2 may be important in the progression and metastasis of colorectal cancer.
|
21133588 |
2010 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
COX-2 and BCRP polymorphisms were not associated with CRC risk.
|
19930591 |
2009 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
|
19491037 |
2009 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To our knowledge this is the first report on ABCG2 and CRC risk.
|
18775442 |
2008 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to determine the involvement of ABCG2 in resistance to SN38 (the active metabolite of irinotecan) in colorectal cancer.
|
15027118 |
2004 |